Guggenheim raised the firm’s price target on Medpace to $464 from $453 and keeps a Buy rating on the shares after an EBITDA and EPS beat-and-raise was supported by “generally positive commentary” on the call. Demand remains strong and Medpace has found ways to be more efficient, meeting its demand needs with lower headcount growth, adds the analyst, who notes that management continues to expect the current environment to support accelerating revenue growth in 2025.